Skip to main content

Homocysteinemia and Hypertension

  • Chapter
  • First Online:
The Clinical Application of Homocysteine
  • 327 Accesses

Abstract

Homocysteinemia causes vascular wall remodelling by altering the elastin/collagen ratio and by changing the molecular characteristics of the proteoglycans, both of which are brought about by various mechanisms. Consequently, vascular compliance is altered and blood pressure increases.

Homocysteinemia is also implicated in pregnancy-induced hypertension and associated with a higher risk of complications.

Several antihypertensives like telmisartan (an angiotensin receptor blocker) and 5-aza-2′-deoxycytidine are known to reduce blood pressure by inhibiting homocysteinemia-induced vascular remodelling. Moreover, MMP-9 (its increased expression is induced by homocysteinemia) has been demonstrated to be involved in development of hypertensive cerebropathy and, hence, MMP-9 inhibitors may be used to ameliorate blood pressure as well as to help prevent cerebropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Atif A, Rizvi MA, Tauheed S, Aamir I, Majeed F, Siddiqui K, Khan S. Serum homocysteine concentrations in patients with hypertension. Pak J Physiol. 2008;4(1):21–2.

    Google Scholar 

  • Bowman TS, Gaziano JM, Stampfer MJ, Sesso HD. Homocysteine and risk of developing hypertension in men. J Hum Hypertens. 2006;20:631–4.

    Article  CAS  Google Scholar 

  • Jain S, Hari Ram V, Kumari S, Khullar M. Plasma homocysteine in Indian patients with essential hypertension and their siblings. Ren Fail. 2003;25(2):195–201.

    Article  CAS  Google Scholar 

  • Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr. 2000;130:377S–81S.

    Article  CAS  Google Scholar 

  • Kalani A, Pushpakumar SB, Vacek JC, Tyagi SC, Tyagi N. Inhibition of MMP9 attenuates hypertensive cerebrovascular dysfunction in Dahl salt-sensitive rats. Mol Cell Biochem. 2016;413(1–2):25–35.

    Article  CAS  Google Scholar 

  • Laskowska M, Oleszczuk J. Homocysteine in pregnancies complicated with pre-ecclampsia with or without IUGR: a comparison with normotensive pregnant women with isolated IUGR and healthy pregnant women. OJOG. 2011;1:191–6.

    Article  CAS  Google Scholar 

  • Lim U, Cassano PA. Homocysteine and blood pressure in the third national health and nutrition examination survey, 1988–1994. Am J Epidemiol. 2002;156(12):1105–13.

    Article  Google Scholar 

  • Narayanan N, Pushpakumar SB, Givvimani S, Kundu S, Metreveli N, James D, Bratcher AP, Tyagi SC. Epigenetic regulation of aortic remodeling in homocysteinemia. FASEB J. 2014;28(8):3411–22.

    Article  CAS  Google Scholar 

  • Noto R, Neri S, Noto Z, Cilio D, Abate G, Noto P, Pepi F, Leanza A, Molino G. Homocysteinemia in pre-ecclampsia is associated to higher risk pressure profiles. Eur Rev Med Pharmacol Sci. 2003;7(3):81–7.

    CAS  PubMed  Google Scholar 

  • Sen U, Tyagi SC. Homocysteine and hypertension in diabetes: does PPAR have a role? PPAR Res. 2010. https://doi.org/10.1155/2010/806538..

  • Sundstrom J, Sullivan L, D’Agostino RB, Jacques PF, Selhub J, Rosenberg IH, Wilson PWF, Levy D, Vasan RS. Plasma homocysteine, hypertension incidence and blood pressure tracking: the framingham heart study. Hypertension. 2003;42:1100–5.

    Article  Google Scholar 

  • Veeranki S, Gandhapudi SK, Tyagi SC. Interaction of homocysteinemia and T cell immunity in causation of hypertension. Can J Physiol Pharmacol. 2016;38:1–8.

    Google Scholar 

  • Weber GJ, Pushpakumar S, Tyagi SC, Sen U. Homocysteine and hydrogen sulphide in epigenetic, metabolic and microbiota related renovascular hypertension. Pharmacol Res. 2016;113(Pt A):300–12.

    Article  CAS  Google Scholar 

  • Xu S, Song H, Huang M, Wang K, Xu C, Xie L. Telmisartan inhibits the proinflammatory effects of homocysteine on human endothelial cells through activation of peroxisome proliferator-activated-receptor-δ pathway. Int J Mol Med. 2014;34(3):828–34. https://doi.org/10.3892/ijmm.2014.1834.

    Article  CAS  PubMed  Google Scholar 

  • Yelikar KA, Deshpande SS, Kulkarni ML. Association of maternal homocysteine level with severity of pre-ecclampsia: a case-control study. Int J Reprod Contracept Obstet Gynecol. 2016;5(8):2713–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bhargava, S. (2018). Homocysteinemia and Hypertension. In: The Clinical Application of Homocysteine. Springer, Singapore. https://doi.org/10.1007/978-981-10-7632-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7632-9_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7631-2

  • Online ISBN: 978-981-10-7632-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics